LivaNova PLC

NASDAQ:LIVN

Medical - Devices

Healthcare
$94.54 +0.96%

+$0.76 today

Market cap
$5.21B
Beta
0.88
P/E (TTM)
40.5
EPS (TTM)
$1.96
52W Low $41.02High $80.96

Volume 1.32M

Average 0.79M

LIVN EBITDA Margin

EBITDA as a percentage of revenue.

LivaNova PLCNASDAQ: LIVN

EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026

EBITDA Margin narrows to 13.9%

EBITDA Margin was 13.9% in Q3 FY2026, down 2.8 pp from a year earlier. On a trailing-twelve-month basis it was 14.0%, up 20.0 pp year over year. Over 3 fiscal years it narrowed by 12.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 8 analysts of 27.8% for the fiscal year ending Dec 2026, up from -9.3% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterSep 2026
13.9%+2.7 pp QoQ
Last fiscal yearDec 2025
-9.3%-25.5 pp YoY
LTMSep 2026
14.0%+20.0 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-2.8 pp+8.6 pp+11.4 pp
1 year-25.5 pp+37.1 pp+62.6 pp
3 years-12.4 pp+38.2 pp+50.6 pp
5 years+39.8 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-9.3%
Year-over-year change
-25.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How LIVN compares with its peers on the latest reported figures

  • LIVN's LTM Sep 2026 EBITDA Margin of 14.0% is the 6th highest of the 10 companies compared; the peer median is 19.3%.
  • Its year-over-year change of +20.0 pp is the 2nd highest of 10, against a peer median of +1.0 pp.
  • Over three fiscal years its change of -12.4 pp compares with a peer median of +5.9 pp.
LIVN Competitors Peer median
EBITDA Margin for LIVN and competitors
Company Period LTM level YoY 3-year change
RMDResMed Inc.LTM Jun 202638.3% +1.0 pp+5.9 pp
BSXBoston Scientific CorporationLTM Jun 202627.6% +2.2 pp+3.8 pp
MDTMedtronic plcLTM Jul 202627.3% +0.0 pp-0.9 pp
EWEdwards Lifesciences CorporationLTM Jun 202624.3% -7.1 pp-12.4 pp
HAEHaemonetics CorporationLTM Jun 202619.3% -8.7 pp-2.2 pp
LIVNLivaNova PLCLTM Sep 202614.0% +20.0 pp-12.4 pp
INSPInspire Medical Systems, Inc.LTM Jun 20269.2% -0.9 pp+18.7 pp
NPCENeuroPace, Inc.LTM Mar 2026-13.9% +3.1 pp+68.3 pp
STIMNeuronetics, Inc.LTM Mar 2026-17.0% +26.6 pp+30.8 pp
CVRXCVRx, Inc.LTM Mar 2026-77.8% +9.1 pp+98.8 pp
MOBIMobia Medical, Inc. Common Stock—— ——
Peer median (excluding LIVN) 19.3%+1.0 pp+5.9 pp

Competitors are the stored peer set for LIVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.04B1.02B1.15B1.25B1.39B
Cost of Revenue329.37M314.58M382.3M382.56M448.2M
Gross Profit705.99M707.23M771.25M870.87M939.9M
Gross Margin68.2%69.2%66.9%69.5%67.7%
Research & Development183.41M155.81M193.82M182.51M185.8M
Selling, General & Admin471.9M469.24M518.13M526.27M548.8M
Operating Expenses706.78M783.98M839.75M741.82M740.5M
Depreciation & Amortization67.99M57.8M60.86M51.14M42M
EBITDA(6.33M)30.9M38.48M202.52M(129.5M)
EBITDA Margin-0.6%3.0%3.3%16.2%-9.3%
Operating Income(784K)(76.75M)(68.5M)129.05M199.4M
Operating Margin-0.1%-7.5%-5.9%10.3%14.4%
Interest Income435K4.7M22.01M30.08M18.98M
Interest Expense50.15M48.25M58.85M63.07M49.29M
Other Income / Expenses(123.84M)1.56M(12.83M)(40.74M)(420.2M)
Income Before Tax(124.62M)(75.2M)(81.33M)88.31M(220.8M)
Pre-Tax Margin-12.0%-7.4%-7.1%7.0%-15.9%
Income Tax Expense11.2M11.05M(98.88M)25.06M21.6M
Net Income(135.82M)(86.25M)17.55M63.23M(242.5M)
Net Margin-13.1%-8.4%1.5%5.0%-17.5%
EPS (Basic)(2.68)(1.61)0.331.17(4.45)
EPS (Diluted)(2.68)(1.61)0.321.16(4.45)
Weighted Avg Shares50.63M53.5M53.9M54.24M54.5M
Weighted Avg Shares (Diluted)50.63M53.5M54.21M54.57M54.5M

LivaNova PLC

NASDAQ:LIVN

Intrinsic Alpha fair value

Locked

Current Price

$94.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.